BR112014009785A8 - método para tratar ou reduzir efp - Google Patents

método para tratar ou reduzir efp Download PDF

Info

Publication number
BR112014009785A8
BR112014009785A8 BR112014009785A BR112014009785A BR112014009785A8 BR 112014009785 A8 BR112014009785 A8 BR 112014009785A8 BR 112014009785 A BR112014009785 A BR 112014009785A BR 112014009785 A BR112014009785 A BR 112014009785A BR 112014009785 A8 BR112014009785 A8 BR 112014009785A8
Authority
BR
Brazil
Prior art keywords
collagenase
treat
reduce
vet
pfe
Prior art date
Application number
BR112014009785A
Other languages
English (en)
Other versions
BR112014009785B1 (pt
BR112014009785A2 (pt
Inventor
G Emeigh Hart Susan
Original Assignee
Auxilium Int Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium Int Holdings Inc filed Critical Auxilium Int Holdings Inc
Publication of BR112014009785A2 publication Critical patent/BR112014009785A2/pt
Publication of BR112014009785A8 publication Critical patent/BR112014009785A8/pt
Publication of BR112014009785B1 publication Critical patent/BR112014009785B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Abstract

colagenase para uso em um método para tratar ou reduzir efp a presente invenção é dirigida a um método para tratar ou reduzir pfe em um paciente que compreende administrar uma ou múltiplas injeções de baixa dose de colagenase a uma área afetada por pfe. a invenção abrange métodos em que a dose de colagenase por injeção está entre cerca de 50 a cerca de 200 unidades abc e/ou em que a concentração de colagenase está entre cerca de 50 a cerca de 2000 unidades abc/mililitro (ml).
BR112014009785-2A 2011-10-21 2012-10-19 método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef) BR112014009785B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
US61/549,863 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Publications (3)

Publication Number Publication Date
BR112014009785A2 BR112014009785A2 (pt) 2017-04-25
BR112014009785A8 true BR112014009785A8 (pt) 2020-02-27
BR112014009785B1 BR112014009785B1 (pt) 2020-06-30

Family

ID=48141393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009785-2A BR112014009785B1 (pt) 2011-10-21 2012-10-19 método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef)

Country Status (15)

Country Link
US (1) US20140335072A1 (pt)
EP (2) EP3581199B1 (pt)
JP (4) JP2014530873A (pt)
AU (5) AU2012325941A1 (pt)
BR (1) BR112014009785B1 (pt)
CA (1) CA2852942C (pt)
DK (2) DK2768523T3 (pt)
ES (2) ES2741476T3 (pt)
FI (1) FI3581199T3 (pt)
HK (1) HK1201439A1 (pt)
HU (2) HUE063599T2 (pt)
MX (2) MX2014004792A (pt)
PL (1) PL3581199T3 (pt)
PT (2) PT3581199T (pt)
WO (1) WO2013059619A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ750379A (en) 2012-01-12 2022-10-28 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
CN104271152B (zh) 2012-05-01 2016-08-17 普罗泰奥里斯有限公司 拔出牙齿的方法
EP3834840A1 (en) 2013-03-15 2021-06-16 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
BR112019018277A2 (pt) 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
MX2019011574A (es) * 2017-03-28 2019-12-19 Endo Ventures Ltd Método mejorado para producir aplicaciones relacionadas con la colagenasa.
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020023406A1 (en) * 2018-07-23 2020-01-30 Nc8, Inc. Cellulite treatment system and methods
EP3852715A1 (en) * 2018-09-18 2021-07-28 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
BR112021012675A2 (pt) * 2019-01-06 2021-09-28 Endo Global Aesthetics Limited Formulação, formulação liofilizada, formulação reconstituída e kit
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2008101406A1 (en) * 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction

Also Published As

Publication number Publication date
PT3581199T (pt) 2023-08-31
HUE044650T2 (hu) 2019-11-28
AU2012325941A1 (en) 2014-05-15
MX2019007779A (es) 2019-09-04
EP2768523A1 (en) 2014-08-27
AU2017248451A1 (en) 2017-11-02
FI3581199T3 (fi) 2023-08-18
JP2018027968A (ja) 2018-02-22
HUE063599T2 (hu) 2024-01-28
PL3581199T3 (pl) 2023-09-11
WO2013059619A1 (en) 2013-04-25
NZ759819A (en) 2020-11-27
CA2852942A1 (en) 2013-04-25
CA2852942C (en) 2023-01-10
NZ722722A (en) 2019-05-31
AU2017248451B2 (en) 2019-11-14
EP3581199B1 (en) 2023-05-31
JP2014530873A (ja) 2014-11-20
BR112014009785B1 (pt) 2020-06-30
JP2022123073A (ja) 2022-08-23
US20140335072A1 (en) 2014-11-13
NZ769098A (en) 2022-03-25
HK1201439A1 (en) 2015-09-04
ES2741476T3 (es) 2020-02-11
DK3581199T3 (da) 2023-09-04
EP3581199A1 (en) 2019-12-18
BR112014009785A2 (pt) 2017-04-25
JP2020158521A (ja) 2020-10-01
MX2014004792A (es) 2015-08-14
ES2953560T3 (es) 2023-11-14
NZ737403A (en) 2020-05-29
PT2768523T (pt) 2019-08-29
AU2016202026A1 (en) 2016-04-21
EP2768523A4 (en) 2015-04-22
AU2022202987A1 (en) 2022-05-26
DK2768523T3 (da) 2019-07-22
AU2020200763B2 (en) 2022-05-26
AU2020200763A1 (en) 2020-02-20
NZ624057A (en) 2016-08-26
EP2768523B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
BR112014009785A8 (pt) método para tratar ou reduzir efp
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
BR112014015955A2 (pt) uso terapêutico subcutâneo de inibidor de dpp-4
CO2017011564A2 (es) Métodos y kits para tratar la depresión
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
MX2021000898A (es) Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe).
BR112014000392A2 (pt) tratamento com anticorpos anti-pcsk9
BR112014014529A2 (pt) métodos para melhorar terapias médicas
BR112014010803A2 (pt) método de tratamento
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
AR084938A1 (es) Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
BR112012021905A2 (pt) tratamento de nefrite lúpica usando laquinimod
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
AR101740A1 (es) Terapia de combinación y composiciones
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112014030279A2 (pt) métodos para tratamento de neutropenia usando agonistas retinóide
BR112016004118A2 (pt) uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A61K 38/48

Ipc: A61K 8/66 (2006.01), A61K 38/48 (2006.01), A61Q 19

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/10/2012, OBSERVADAS AS CONDICOES LEGAIS.